Friday, June 12, 2026
HomeLatest"UK Study Reveals Stigma of Weight Loss Meds"

“UK Study Reveals Stigma of Weight Loss Meds”

A recent study conducted by digital healthcare provider Voy uncovered that over half of individuals in the UK who have used GLP-1 weight loss medication have kept it a secret. The research also revealed that 83% of eligible adults believe there is a social stigma associated with taking weight loss medication, leading many to hide their usage, especially of injectables like Mounjaro or Wegovy, from their loved ones due to fear of judgment.

With the launch of a new oral GLP-1 weight loss pill in the UK, users are hopeful for a more discreet treatment option. Respondents expressed concerns that using weight loss medication might lead others to assume they are taking shortcuts or lack self-discipline, emphasizing that weight loss should ideally result from lifestyle changes.

Despite the potential health benefits of GLP-1 medication, practical barriers hinder some individuals from opting for this treatment. Factors such as fear of injections, cost issues, and worries about side effects have deterred 15%, 59%, and 32% of respondents, respectively.

Voy suggests that the introduction of oral GLP-1 treatments could revolutionize the perception and accessibility of weight management support, offering a more affordable and convenient alternative. The research indicates that 69% of eligible adults would prefer a daily oral weight loss medication over a weekly injection.

Dr. Earim Chaudry, Chief Medical Officer at Voy, emphasized the importance of the new oral GLP-1 medication in expanding treatment options and potentially breaking down barriers to care. While the oral pill may make treatment less conspicuous, societal attitudes towards obesity need to evolve beyond mere treatment formats to combat stigma effectively.

The changing landscape of obesity treatment highlights the need for a shift in societal perceptions towards the condition, focusing on evidence-based discussions rather than misconceptions. The introduction of new treatment options is a step forward, but addressing the stigma associated with obesity requires a comprehensive change in societal attitudes at all levels.

RELATED ARTICLES

Most Popular